X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/09/2859907/0/en/NewAmsterdam-Pharma-Enrolls-Over-9-000-Patients-in-Pivotal-Phase-3-PREVAIL-Global-Cardiovascular-Outcome-Trial-Evaluating-the-Effect-of-Obicetrapib-in-Patients-with-Established-Ath.html
https://www.globenewswire.com//news-release/2024/03/12/2844471/0/en/NewAmsterdam-Pharma-Doses-First-Patient-in-Phase-3-TANDEM-Clinical-Trial-Evaluating-Fixed-Dose-Combination-of-Obicetrapib-and-Ezetimibe-in-Patients-with-HeFH-and-or-ASCVD.html
https://www.globenewswire.com//news-release/2023/09/21/2747139/0/en/NewAmsterdam-Pharma-Announces-Initial-Data-from-Phase-2a-Clinical-Trial-Evaluating-Obicetrapib-in-Patients-with-Early-Alzheimer-s-Disease-Who-Carry-an-ApoE4-Mutation.html
https://www.europeanpharmaceuticalreview.com/news/184031/could-obicetrapib-facilitate-sufficient-ldl-cholesterol-levels/
https://www.globenewswire.com/news-release/2023/06/05/2681808/0/en/NewAmsterdam-Pharma-Announces-Positive-Topline-Results-from-Phase-2b-Dose-Finding-Trial-Evaluating-Obicetrapib-in-Japanese-Patients.html
https://www.globenewswire.com/news-release/2023/06/03/2681526/0/en/NewAmsterdam-Pharma-Presents-Full-Data-from-Phase-2-ROSE2-Trial-Evaluating-Obicetrapib-in-Combination-with-Ezetimibe-as-an-Adjunct-to-High-Intensity-Statin-Therapy-at-NLA-Scientifi.html
https://www.globenewswire.com/news-release/2023/04/24/2652638/0/en/NewAmsterdam-Pharma-Completes-Enrollment-in-Pivotal-Phase-3-BROOKLYN-Clinical-Trial-Evaluating-Obicetrapib-in-Patients-with-Heterozygous-Familial-Hypercholesterolemia.html
https://endpts.com/newamsterdam-notches-another-win-in-resurrection-of-amgen-cardio-drug/
https://www.bioworld.com/articles/520155-newamsterdam-secures-1b-plus-european-commercial-deal-with-menarini?v=preview
https://endpts.com/a-forbion-funded-startup-bought-the-rights-to-amgens-cetp-inhibitor-and-is-giving-the-cholesterol-drug-another-go/
https://www.biopharmadive.com/news/newamsterdam-buys-amgen-heart-drug-obicetrapib/584164/
https://www.businesswire.com/news/home/20200825005160/en/NewAmsterdam-Pharma-Acquires-Obicetrapib-Amgen
https://www.biospace.com/article/releases/newamsterdam-pharma-acquires-obicetrapib-from-amgen/?s=79
Market Place
Share 
